The significant upregulation of PTGS2, widely accepted as a primary ferroptosis biomarker, in both CLI tissue and erastin-treated myotubes provides additional evidence that ferroptotic cell death is occurring in the advanced stages of PAD [48]. Here, PTGS2 is linked to peripheral arterial disease.